NEW YORK, March 1, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced today that Dr. Robert Preti, PhD, President and Chief Scientific Officer of Progenitor Cell Therapy ("PCT"), a wholly-owned subsidiary of NeoStem, Inc., has been asked to present on Tuesday, March 1, 2011 at the 6th Annual New York Stem Cell Summit. The Summit will be held at Bridgewaters New York at 11 Fulton Street, New York, NY. Dr. Preti will present as part of the Adult Stem Cell track at 2:11 pm.
Dr. Preti is co-founder of Progenitor Cell Therapy, LLC, an internationally recognized cell therapy services and development company. Through his administrative duties, Dr. Preti has overseen the growth of PCT from its inception to the world's leading commercial cell therapy company. He is one of the country's leading authorities on cell engineering, advanced cell and gene therapy manufacturing, testing and delivery, and regulatory aspects relating to the cell therapy and regenerative medicine industry and has been a pioneer of cell manufacturing as with Dendreon's product Provenge which just received FDA approval in 2010. He has been the principal investigator for a number of clinical trials relating to the clinical testing of cellular therapies. Previous positions held by Dr. Preti include Scientific and Laboratory Director of Hackensack University Medical Center's stem cell processing and research laboratory and Scientific Director of the Clinical Services Division at the New York Blood Center.
The Company acquired PCT in January 2011. PCT, through its cGMP certified manufacturing facilities and team of professionals, facilitates the preclinical and clinical development and eventual commercialization of cellular therapies for clients in the United States and internationally.
Dr. Robert Pret
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved